Log In
BCIQ
Print this Print this
 

ADXS-NEO

  Manage Alerts
Collapse Summary General Information
Company Advaxis Inc.
DescriptionImmunotherapy produced from Listeria monocytogenes attenuated bacterial vector technology containing patient-specific neoepitopes
Molecular Target
Mechanism of Action 
Therapeutic ModalityActive immunotherapy
Latest Stage of DevelopmentPreclinical
Standard Indication Cancer (unspecified)
Indication DetailsTreat cancer
Regulatory Designation
PartnerAmgen Inc.

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

$540.0M

$40.0M

$475.0M


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

08/02/2016

$540.0M

$40.0M

$475.0M

Get a free BioCentury trial today